Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

882.10GBp
11:29am EDT
Change (% chg)

55.10 (+6.66%)
Prev Close
827.00
Open
827.10
Day's High
882.10
Day's Low
780.00
Volume
343,648
Avg. Vol
218,932
52-wk High
1,064.38
52-wk Low
366.00

Chart for

About

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D... (more)

Overall

Beta: -0.51
Market Cap(Mil.): £583.85
Shares Outstanding(Mil.): 65.72
Dividend: --
Yield (%): --

Financials

  OXB.L Industry Sector
P/E (TTM): -- 214.90 33.15
EPS (TTM): -0.15 -- --
ROI: -19.76 -3.85 13.23
ROE: -96.12 -5.38 15.27

BRIEF-Oxford Biomedica Announces ‍Proposed Placing To Raise About 20.5 Mln STG

* OXFORD BIOMEDICA PLC - ‍PROPOSED PLACING TO RAISE APPROXIMATELY £20.5 MILLION​

Mar 09 2018

Oxford BioMedica wins second $100 million gene therapy contract

LONDON Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

Feb 15 2018

Oxford BioMedica wins second $100 mln gene therapy contract

LONDON, Feb 15 Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

Feb 15 2018

Earnings vs. Estimates